|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||159.57 - 161.80|
|52-week range||95.21 - 172.74|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||0.53|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Dividend stocks, on balance, tend to deliver market-beating returns on capital over the long haul. The key reason is that regular dividend payments amplify returns through the power of compounding. Selecting dividend stocks is no easy task, however.
Novo Nordisk (NYSE: NVO) is planning to pause some of its advertising campaigns for its obesity drug Wegovy, due to white-hot demand in the U.S. The impact of the move isn't the marketing costs it saves, but the unambiguous message it sends: Wegovy is probably going to bring in even more sales than management expected -- and it had expected quite a bit. This isn't the first time that demand for Wegovy has been greater than what the pharma can manufacture, and it's no surprise why.
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong mid-stage data for Pfizer's orally administered diabetes and weight loss drug, danuglipron, which were published yesterday in JAMA Network medical journal. Novo's shares have more than doubled in value over the prior two years, thanks to the breakout success of its type 2 diabetes and weight loss drug semaglutide.
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Yahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug.
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Novo Nordisk (NYSE: NVO) is the company behind diabetes and weight-loss treatments Ozempic and Wegovy. Business has been booming as demand for those drugs has left the company in a rush to add capacity so that it can fill orders. On Jan. 2, 2020, shares of Novo Nordisk opened at a price of $58.31.
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Fat-busting injections make investors gush like Hollywood celebs. Research this week suggested obese patients cost Britain’s NHS twice as much as healthy ones. It reckons most of the gains will be made by the two frontrunners, Denmark’s Novo Nordisk and Eli Lilly of the US.
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
The drugmaker's shares have crushed the broader markets over the past two years. Can it keep up this blistering momentum?
Momentum investing is centered around targeting stocks displaying outperformance. And when you add in the Zacks Rank, the strategy can become even more potent.